The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
For most of the twentieth century, the global pharmaceutical industry operated on a straightforward geographic logic. Drugs were discovered and developed in North America and Western Europe, approved by the FDA and EMA, and then exported to the rest of the world. The...
AI developments are happening at breakneck speed, with every sector and industry seeking new opportunities to seize and capitalise upon. AI-driven research is creating a fundamental shift for pharmaceutical competitive intelligence, moving away from a reactive, manual...
The pharmaceutical press is having a very loud year. Eli Lilly's investigational triple-agonist retatrutide has produced the kind of phase 2 data that clinicians usually only see in editorials about the future, up to 24.2% mean body-weight reduction at 48 weeks in the...
AstraZeneca China Obesity Drug Deal: A $18.5 Billion Bet on the Future of Weight Management AstraZeneca announced on 30 January 2026, what has quickly become known as the AstraZeneca CSPC obesity deal, a landmark licensing and collaboration agreement with China's CSPC...
AstraZeneca China Obesity Drug Deal: A $18.5 Billion Bet on the Future of Weight Management AstraZeneca announced on 30 January 2026, what has quickly become known as the AstraZeneca CSPC obesity deal, a landmark licensing and collaboration agreement with China's CSPC...
Oncology drug development is more mechanistically advanced than ever. Scientists and researchers design therapies to block immune evasion, disrupt tumor metabolism, and rewire the microenvironment. Yet a costly problem remains: many patients who should respond to...
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...
Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....
Pharma generates more insight than ever. Translating that insight into timely action is where the system falters, and the gap runs deeper than most commercial leaders are willing to admit. Over the past decade, omnichannel systems have matured considerably. CRM...
The biopharma industry is at an inflection point as it enters 2026. Discoveries from the past year will be applied and scaled, particularly across AI-enabled drug development, advanced modalities and cardiometabolic disease treatment. These advancements will occur...
GLP-1 medications have changed the landscape of weight management. For many people, they have delivered clinically meaningful weight loss alongside improvements in glycaemic control, and their place in treatment pathways is now well established. What is becoming...
Against a backdrop of rising development and launch costs, growing regulatory complexity, geopolitical uncertainty and intensifying competition for specialist talent, many European pharma and biotech companies are reassessing the long-held ambition of “cracking the...
Johnson & Johnson has announced plans to invest more than $1 billion in a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. This project marks a significant expansion of its advanced therapies infrastructure and reinforces the company’s...